Design, Construction and Immunogenicity Assessment of pEGFP-N1-KMP11-GP96 (Fusion) as a DNA Vaccine Candidate against Leishmania major Infection in BALB/c Mice

  • Abdolhossein DALIMI Department of Parasitology and Entomology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • Vahid NASIRI Department of Parasitology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Exten-sion Organization, Karaj, Iran
Keywords:
Leishmania major, Fusion gene, Vaccine

Abstract

Background: KMP-11 (Kinetoplastid membrane protein-Π) exists in all species of kinetoplastid family. It is fully conserved and the protein produced by this gene can induce a very high cellular immune response. We aimed to design a suitable construction for a Leishmania major DNA vaccine and evaluate the protective efficacy of it as a candidate for DNA vaccine against cutaneous leishmaniasis in BALB/c mice. Methods: This experimental study was conducted in Tehran City, Iran, between April 20, 2015 and May 30, 2016. KMP-11 gene of L. major (MRHO/IR/75/ER, Iranian strain) and NT-GP96 of Xenopus GP96 DNA from a pBluescript-GP96 plasmid were amplified by PCR and the purified PCR products were cloned into the pJET1.2/blunt plasmid vector, then, subcloned into pEGFP-N1 plasmid as an expression vector. Finally, the KMP-11 gene was fused with GP96 and afterward the combination cloned in pEGFP-N1. All the cloned genes confirmed by enzyme digestions. Then, four groups of mice were immunized with PBS, pEGFP-N1, pEGFP-N1-KMP, and pEGFP-N1-fusion. Four weeks after immunization, all animals were challenged with L. major virulent promastigotes. Results: The constructed fusion potentially showed an ability to elicit Th1 responses that led to cutaneous lesion healing. Interestingly, the group received KMP11-GP96 –GFP showed the highest ratio of IFN- γ /IL-4 and IgG2a/IgG1 compare to other groups. No side effect was observed after using the fusion in the mice. Conclusion: The constructed fusion could well stimulate both the cellular and humoral immune systems that led to cutaneous lesion healing in mice.

References

1. Mohebali M, Kazemirad E, Hajjaran H, et al. Gene expression analysis of antimony resistance in Leish-mania tropica using quantitative real-time PCR fo-cused on genes involved in trypanothione metabo-lism and drug transport. Arch Dermatol Res. 2019; 311(1):9–17.
2. Connell ND, Medina-Acosta E, McMaster WR et al. Effective immunization against cutaneous leish-maniasis with recombinant bacilli Calmette Guerin expressing the Leishmania surface protein gp63. Proc Natl Acad Sci. 1993; :11473-7.
3. Skeiky YA, Benson DR, Guderian JA et al. Im-mune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun.1995; 63(10): 4105-14.
4. Webb JR, Campos-Neto A, Ovendale PJ et al. Human and murine immune responses to a novel L. major recombinant protein encoded by members of a multicopy gene family. Infect Immunol. 1998; 66:3279.
5. Sjolander A, Baldwin TM, Curtis J, Handman E. Induction of a Th1 immune response and simulta-neous lack of activation of a Th2 response are re-quired for generation of immunity to leishmaniasis. J Immunol. 1998;160: 3949.
6. Solioz N, Blum-Tirouvanziam U, Jacqute R et al. The protective capacities of histon H1 against ex-perimental murine cutaneous leishmaniasis. Vac-cine. 1999; 18: 850-859.
7. Ziaee Hezarjaribi H, Ghaffarifar F, Dalimi A et al. Effect of IL-22 on DNA vaccine encoding LACK gene of L. major in BALB/c mice. Exp Parasitol. 2013;134 :341–348.
8. Jorjani O, Ghaffarifar F, Sharifi Z et al. LACK Gene’s immune response induced by cocktail DNA vaccine with IL-12 gene against cutaneous leishmaniasis in BALB/c mice. Avicenna J Med Biotechnol. 2018; 10, 3:134-140.
9. Ghaffarifar F, Jorjani O, Sharifi Z et al. Enhance-ment of immune response induced by DNA vac-cine cocktail expressing complete LACK and TSA genes against Leishmania major. APMIS. 2013;121(4):290-8.
10. Maspi N, Ghaffarifar F, Sharifi Z. Dalimi A. Co-delivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice. Parasite Immunol. 2016; 38:228–235
11. Maspi N, Ghaffarifar F, Sharifi Z et al. Immuno-genicity and efficacy of a bivalent DNA vaccine containing LeIF and TSA genes against murine cu-taneous leishmaniasis. APMIS. 2017a; 125: 249–258.
12. Maspi N, Ghaffarifar F, Sharifi Z et al. Comparative assessment of induced immune responses follow-ing intramuscular immunization with fusion and cocktail of LeIF, LACK and TSA genes against cu-taneous leishmaniasis in BALB/c mice. Arch Im-munol Therap Exp. 2018 ,66(1):55-64.
13. Maspi N, Ghaffarifar F, Sharifi Z et al. DNA vac-cination with a plasmid encoding LACK-TSA fu-sion against Leishmania major infection in BALB/c mice. Malaysian J Pathol. 2017c; 39(3):267–275.
14. King DL, Chang YD, Turco SJ. Cell surface lipo-phosphoglycan of Leishmania donovani. Mol Biochem Parasitol. 1987; 24: 47-53.
15. Russo DM, Turco SJ, Burns JM Jr, Reed SG. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. J Immunol. 1992; 148: 202-207.
16. Todoli F, Solano-Gallego L, de Juan R et al. Hu-moral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum anti-gens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area. Am J Trop Med Hyg. 2010; 83 (6):1287–94.
17. Yang Y, Li Z. Roles of heat shock protein GP96 in the ER quality control: redundant or unique func-tion? Mol Cells. 2005; 20 (2):173-182.
18. Binder RJ, Vatner R, Srivastava P. The heat-shock protein receptors: some answers and more ques-tions. Tissue Antigens. 2004; 64:442–451
19. Li HT, Yan JB, Li J et al. Enhancement of humoral immune responses to HBsAg by heat shock pro-tein GP96 and its N-terminal fragment in mice. World J Gastroenterol. 2005; 11:2858–2863.
20. Nasiri V, Dalimi A, Ghaffarifar F, et al. Immuno-genicity and efficacy of live L. arentolae expressing KMP11-NTGP96 -GFP fusion as a vaccine candi-date against experimental viscer-al leishmaniasis caused by L. Infantum. Iran J Parasi-tol. 2016; 11(2): 144–158.
21. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in In-dia: report from the center of the Indian epidemic. Clin Infect Dis. 2000; 31(4):1104-7.
22. Garmory HS, Brown KA, Titball RW. DNA vac-cines: improving expression of antigens. Genet Vaccines Ther. 2003; 1(1):2.
23. WHO. Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, 22-26 March 2010, no. 949. p. 186.
24. Nagill R, Kaur S. Vaccine candidates for leishmani-asis: a review. Int Immunopharmacol. 2011; 11(10):1464–88.
25. Borja-Cabrera GP, Santos FN, Bauer FS et al. Im-munogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vac-cine. 2008; 26(39): 4991–7.
26. Trujillo C, Ramirez R, Velez ID, Berberich C. The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease prevalence of IgG subclasses and mapping of epitopes. Immunol Lett.1999; 70:203-209.
27. Ramirez JR, Gilchrist K, Robledo S et al. Attenuat-ed Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a spe-cific immune response in BALB/c mice. Vaccine. 2001; 20:455-461.
28. Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmania major in mice: Implications for immune memory, vaccination, and reactivation disease. J Immunol. 2001; 167, 6967–6974.
29. Yamakami K, Akao S, Sato M et al. A single intra-dermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection. Par-asitol Int. 2001; 50, 81–91.
30. Jaafari MR, Ghafarian A, Farrokh-Gisour A et al. Immune response and protection assay of recom-binant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine. 2006; 24, 5708–5717.
Published
2020-03-09
How to Cite
1.
DALIMI A, NASIRI V. Design, Construction and Immunogenicity Assessment of pEGFP-N1-KMP11-GP96 (Fusion) as a DNA Vaccine Candidate against Leishmania major Infection in BALB/c Mice. Iran J Parasitol. 15(1):11-21.
Section
Original Article(s)